title: Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0.
abstract: Acute regimen-related toxicity (RRT) is minimal in reduced-intensity stem-cell transplantation (RIST). However, the Seattle RRT grading (Bearman et al), developed in the context of conventional-intensity transplantation, is frequently applied to RIST. We compared the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 with the Seattle criteria after RIST in 86 patients. RRT within 30 days of transplant graded by both sets of criteria were significantly associated with the outcome confirming the predictive value of both the systems. A total of 15 patients died of disease progression, and 12 of transplant-related mortality: RRT (n = 2), graft-versus-host disease (GVHD) (n = 7), infection (n = 1), and others (n = 2). GVHD-related deaths primarily resulted from infections after steroid treatment (n = 6) and bronchiolitis obliterans (n = 1). This study shows that NCI-CTC is appropriate in toxicity evaluation of RIST, and that its application to RIST enables a toxicity comparison between RIST and other types of cancer treatments. Since GVHD is a significant problem in RIST, modifications are required to evaluate immunological complications following RIST.
authors.affiliation: Hematopoietic Stem Cell Transplantation Unit, The National Cancer Center Hospital, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sakiyama
authors.forename: M
authors.initials: M
authors.lastname: Kami
authors.forename: A
authors.initials: A
authors.lastname: Hori
authors.forename: O
authors.initials: O
authors.lastname: Imataki
authors.forename: T
authors.initials: T
authors.lastname: Hamaki
authors.forename: N
authors.initials: N
authors.lastname: Murashige
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kishi
authors.forename: R
authors.initials: R
authors.lastname: Kojima
authors.forename: S-W
authors.initials: SW
authors.lastname: Kim
authors.forename: E
authors.initials: E
authors.lastname: Kusumi
authors.forename: K
authors.initials: K
authors.lastname: Yuji
authors.forename: S
authors.initials: S
authors.lastname: Miyakoshi
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: R
authors.initials: R
authors.lastname: Tanosaki
authors.forename: S
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Takaue
mesh_terms: D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007564:Japan; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods* / Q000401:mortality; D016019:Survival Analysis; D014861:Washington